A Phase 2, Randomized, Double-blind, Dose Finding Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2017
At a glance
- Drugs DS-8500 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 07 Jun 2017 Biomarkers information updated
- 10 Jan 2017 Status changed from active, no longer recruiting to completed.
- 22 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.